Table 4

Cox proportional regression for the development of peripheral disease among PsA patients who presented with isolated axial disease at first presentation of axial disease adjusted by sex and age at diagnosis of PsA (N=32)

VariableUnivariate model
HR95% CIP value
Sex (male)
Age at diagnosis of PsA in years
Sacroiliitis grade*0.899(0.466 to 1.733)0.751
Enthesitis0.940(0.121 to 7.342)0.953
Elevated ESR0.626(0.230 to 1.708)0.360
Nail lesion0.826(0.319 to 2.141)0.694
PASI1.030(0.960 to 1.106)0.408
Uveitis2.130(0.786 to 5.769)0.137
HLA-B*271.069(0.394 to 2.901)0.896
NSAIDS1.009(0.434 to 2.346)0.983
DMARDS0.825(0.341 to 1.993)0.669
Biologics1.137(0.381 to 3.392)0.818
  • *The sacroiliac joint with the highest grade was used preferentially for analysis.

  • DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; PASI, psoriasis area and severity index; PsA, psoriatic arthritis.